Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Indication
In combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs including methotrexate or a tumour necrosis factor (TNF)-alpha inhibitor.
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
250mg powder for concentrate for solution for infusion
Comments
July 2013 - Included on the Additional List, Specialist Use only, for the indication in question. January 2016 - NICE MTA advice: SMC advice 719/11 is superseded by NICE TA375. July 2019 (as per LJF) - Routinely available in line with national guidance. Included on the Additional List, for Specialist Use only.
Link to Advice
Advice Published
26/01/2016